You Treat Your Patients as Individuals. So Do We.

Most men with an elevated PSA will have a prostate biopsy negative for clinically significant cancer.

You regularly grapple with the decision whether to proceed with biopsies in men with an elevated PSA. You know most of these men do not have clinically significant prostate cancer, but incomplete information keeps you from knowing who is truly at risk. And, under the traditional “biopsy all” approach, 75% of prostate biopsies are negative for clinically significant cancer. With stakes so high, you need the insights provided by the next generation of biomarker testing.

MyProstateScore 2.0 (MPS2) is the most comprehensive and flexible prostate cancer risk assessment tool, optimized for unrivaled accuracy for both previous negative biopsy and biopsy naïve patients, providing unparalleled insights to guide clinical decisions.

93%-99% NPV, depending on clinical context

Patients with a history of a negative prostate biopsy who present with persistently elevated or increasing PSA results, and/or suspicious DRE findings, present a unique clinical challenge.

Historically, biomarker tests and risk assessment tools have suffered from an absence of data or diminished performance in this complex repeat biopsy population.

Lynx Dx has developed MyProstateScore 2.0 (MPS2), which combines the predictive power of 18 urine biomarkers with those clinical factors most relevant to repeat biopsy patients to produce the first biomarker test with 99% NPV for the prediction of Grade Group ≥ 2 prostate cancer in patients with a previous negative biopsy.

Lynx Dx and its research partners at the University of Michigan are dedicated to the highest quality of research excellence, including the breakthrough discovery of the novel T2:ERG gene fusion for which Dr. Arul Chinnaiyan was awarded the 2022 Sjoberg Prize.